ClinicalTrials.gg
RecruitingNCT06625385Updated Feb 13, 2026

A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing

An interventional study of 3M™ V.A.C.® Peel and Place Dressing in Wound, sponsored by Solventum US LLC. Recruiting at 3 sites in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.

Read the detailed description

This is a prospective, post-market, multi-center, single-arm study. A target of 90 enrolled Subjects with 1 enrolled study wound per Subject is planned for this study, including 60 open wounds (10 for each type of open wound) and 30 closed or covered wounds (10 for each type of closed/covered wound). The entire duration of the study is expected to last approximately 2 years. Individual Subject participation is expected to last up to 20 days, including a screening period lasting up to 5 days, the day of initial treatment, dressing change visits as clinically appropriate but no more than 7 days from dressing application, and an end-of-treatment (EOT)/end-of-study (EOS) visit between Day 7 and Day 14 after the initial dressing application.

02

Conditions studied

  • Wound

Browse trials for

Keywords

  • Open
  • Closed
03

In context

Wounds and Injuries

2,220 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 90 is above the median of 70 across 1,425 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is at least 22 years old at the time of consent.
  2. Subject or legally authorized representative (LAR) is able to provide .
  3. Subject has a wound deemed appropriate for treatment with a V.A.C.® Peel and Place dressing (used in conjunction with 3M™ V.A.C.® Therapy), according to the instructions for use for the dressing, including the following wound types:

    • an open wound: traumatic wound, dehisced surgical wound within 30 days of surgery, burn, venous ulcer, diabetic ulcer, or pressure ulcer Note: Prior to initial placement, the wound may be debrided, as clinically indicated
    • a closed or covered wound secured with sutures or staples: closed surgical incision, skin flap closure, or skin graft (recipient site)
  4. Subject is willing and able to attend all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or lactating prior to application of the initial dressing. *

    *Women who have had surgical sterilization by a medically accepted method (ie, tubal ligation, hysterectomy, or oophorectomy) or are , defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing.

  2. Subject is participating in another interventional clinical study or was enrolled in a clinical trial within the last 30 days before screening.
  3. Subject has been diagnosed with a in the wound.
  4. Subject has untreated osteomyelitis or untreated cellulitis in the wound.
  5. Subject has an untreated systemic infection.
  6. Subject has active cellulitis in the peri-wound area.
  7. Subject has a known allergy or to study materials: dressing(s), and/or dressing components such as acrylic or silicone adhesives or polyurethane.
  8. Subject has, in the opinion of the investigator, a condition that would impair the Subject's ability to comply with the study procedures or would compromise assessment of endpoints (wound/peri-wound condition).
  9. Subject has had radiation directly to the wound area.
  10. Subject received hyperbaric oxygen therapy within 30 days before the initial application of a V.A.C.® Peel and Place dressing.
  11. Subject has been diagnosed with a major vascular deficit limiting arterial inflow into the wound region, as determined by the investigator's interpretation of the subject's medical history.
  12. In the case of a lower extremity wound, the Subject has one of the following:

    • an ankle brachial index \< 0.8;
    • no palpable pulse; or
    • no discernable audio Doppler signal.

Individual wounds are to be excluded from the study if they meet any of the following criteria

  1. Wound has necrotic tissue and/or eschar present. NOTE: After debridement of necrotic tissue and complete removal of eschar, the V.A.C.® Peel and Place dressings may be used.
  2. Wound contains a non-enteric or unexplored fistula(s) in the wound bed.
  3. Wound has tunneling.
  4. Wound has undermining that is ≥ 2 cm in any direction from the wound edge.
  5. Wound site has inadequate hemostasis, as determined by the investigator.
  6. Wound has exposed vessels, anastomotic sites, organs, or nerves that cannot be protected prior to placement of the V.A.C.® Peel and Place Dressings.
  7. Wound has a depth greater than 2 cm (for small dressings), 4 cm (for medium dressing size), or 6 cm (for the large dressing size).
  8. The wound received, within 30 days before initiating V.A.C.® Therapy, treatment with any of the following:

    • any previous negative pressure wound therapy device.
    • growth factors.
    • bioengineered tissue products, eg, skin or dermal substitutes.
  9. Wound was closed with tissue adhesive.
  10. Wound has, in the opinion of the Investigator, any characteristic that would make it unsuitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    3M™ V.A.C.® Peel and Place Dressing

    3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy

    Device: 3M™ V.A.C.® Peel and Place Dressing

Interventions

  • Device3M™ V.A.C.® Peel and Place Dressing

    Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy

06

What researchers measure

Primary outcomes

  1. Incidence of (ADEs)

    The incidence of adverse device effects (ADEs)

    Time frame: 14 days

Secondary outcomes

  1. Percentage of closed surgical incisions and skin flaps that remain closed

    The percentage of closed surgical incisions and skin flaps that remain closed throughout treatment

    Time frame: 14 days

  2. Percentage of skin grafts with ≥ 90% graft take

    The percentage of skin grafts with ≥ 90% graft take at the end of treatment

    Time frame: 14 days

  3. Percentage of open wounds with evidence of healing

    The percentage of open wounds with evidence of healing, as evidenced by any of the following: * decrease in total wound area (cm2) from baseline to the end of treatment, * decrease in total wound volume (cm3) from baseline to the end of treatment, * decrease in average wound depth from baseline to the end of treatment, * increase in the percentage of the wound with red color composition (signifying healthy, viable tissue), from baseline to the end of treatment, * improved score for exudate amount from the first dressing change to the end of treatment * improved score for peripheral tissue edema from baseline to the end of treatment * new epithelialization from baseline to the end of treatment, or * wound is deemed ready for closure (via delayed primary closure, graft, flap or allowed to epithelialize) at any time from baseline to the end of treatment

    Time frame: 14 days

  4. Overall rate of wound healing for both open wounds and closed/covered wounds

    The overall rate of wound healing for both open wounds and closed/covered wounds, as evidenced by the aforementioned criteria

    Time frame: 14 days

Other outcomes

  1. Pain score associated with dressing removal

    The pain score associated with dressing removal (ie, during dressing changes and at final dressing removal) - Subject-reported and based on the highest level of perceived pain. Whereby a score of 0 is indicative of "no pain" and a score of 10 indicates the "worst pain possible".

    Time frame: 14 days

07

Study locations

3 of 3 sites recruiting
  • IU Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Kaitlyn Depinet, NP · Contact
  • Washington University - Barnes Jewish Hospital
    St Louis, Missouri 63110, United States
    Recruiting
    • Jen McCarthy · Contact
    • Bryan Sato · Contact
  • St. Luke's University Hospital
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Monica Hosler · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 53 industry-sponsored interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 23 months is close to that.

Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Oct 3, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625385
Lead sponsor
Solventum US LLC
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Jan 20, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Eric Synatschk
Contact
esynatschk@solventum.com
346-550-5698
Stephanie Karwedsky
study director · Solventum

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion